Healionics Analysis: $17M Raised
What is Healionics?
Healionics develops the STARgraft vascular graft to improve bloodstream access for dialysis patients. Their proprietary STAR® biomaterial scaffold enhances biointegration and tissue regeneration, addressing issues of occlusion and infection. The company collaborates with leading organizations in kidney treatment and has received FDA Breakthrough Device designation for STARgraft.
Location
2121 N 35th Street, Suite 200, Seattle, Washington 98103, United States
Employees
1-10
Founded
2007
Funding Status
Series A
Product Features & Capabilities
- STARgraft vascular graft
- STAR® biomaterial scaffold
Use Cases
Provide safer dialysis access for kidney failure patients; Reduce occlusion and infection rates in vascular grafts; Collaborate with University of Washington for device innovation; Partner with Northwest Kidney Centers for outpatient dialysis solutions; Enhance quality of life for patients requiring frequent dialysis
HQ Full Address
2121 N 35th Street, Suite 200, Seattle, Washington 98103, United States
Other Considerations
Received FDA Breakthrough Device designation for STARgraft; Collaborates with University of Washington and Northwest Kidney Centers; Focused on improving health outcomes for kidney failure patients
See something that needs updating? Suggest edits to this profile.